Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016-05-10
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Abstract
Purpose
To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin.
Patients and methods
Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sensitive and specific assay. This preplanned 12-month analysis evaluated E2, E1, E1S, follicle-stimulating hormone, and luteinizing hormone levels in all patients and the proportion of patients with E2 levels greater than 2.72 pg/mL at any time point during treatment with exemestane plus triptorelin.
Results
One hundred sixteen patients (exemestane, n = 86; tamoxifen, n = 30; median age, 44 years; median E2, 51 pg/mL; 55% prior chemotherapy) started triptorelin and had one or more samples drawn. With exemestane plus triptorelin, median reductions from baseline E2, E1, and E1S levels were consistently ≥ 95%, resulting in significantly lower levels than with tamoxifen plus triptorelin at all time points. Among patients on exemestane plus triptorelin, 25%, 24%, and 17% had an E2 level greater than 2.72 pg/mL at 3, 6, and 12 months, respectively. Baseline factors related to on-treatment E2 level greater than 2.72 pg/mL were no prior chemotherapy (P = .06), higher body mass index (P = .05), and lower follicle-stimulating hormone and luteinizing hormone (each P < .01).
Conclusion
During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.
Related Questions
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
I avoid the issue by taking a sequential approach. I typically start premenopausal women on tamoxifen, then add OFS 4-6w later depending on their tolerance of tamoxifen, and then change to an AI after another 6-12 weeks. It is easy to underestimate the severity of side effects that many premenopausa...
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
This is a sneaky difficult question. We've known since George Beatson that estrogen was important for breast cancer, and the Early Breast Cancer Trialists Collaborative Group helped get Tamoxifen approved in 1978. I've heard it said that we've had more trials looking at estrogen therapy for breast c...
What would be your preferred dosage and schedule for leuprolide for ovarian suppression alongside endocrine therapy for the treatment of breast cancer?
I usually offer the q4 week or q12 week schedules. With lab monitoring for adequate suppression, the q12 week schedule is often preferred due to less visits to the center. Goserelin at 3.6mg q4 weeks or 10.8mg q12 weeks are usually what I use, occasionally leuprolide. Notably, even with q4 week dosi...
How do you manage ovarian suppression for premenopausal patients with HR+/HER2 positive breast cancer?
Oophorectomy and GnRH agonist are two options for ovarian suppressive therapy. There are two fundamental differences between these options. First, GnRH monthly, and especially the 3-month depot preparations, will incompletely suppress estradiol levels in some women. 17% to 25% of women on monthly Gn...
What is your strategy for ovarian suppression if unable to achieve goal estradiol levels with leuprolide 3.75mg monthly dose?
Monthly therapy rarely fails to induce adequate suppression. The choice of options will depend on whether the patient planned permanent or only temporary suppression AND the risk of recurrence of the cancer. If she will accept permanent suppression and has high risk disease, oopherectomy would be th...
How do you monitor ovarian function in high risk, premenopausal breast cancer patients receiving adjuvant ovarian suppression?
Great question. Extremely clinically relevant. Here's the problem with 'medical oophorectomy': ABCSG-12 showed that OFS+AI in premenopausal women who were overweight had a 50% increased risk for disease recurrence. SOFT trial sub-study, SOFT-EST, showed that one in three women on OFS+AI have subopti...